Home/Spexis/Jeffrey D. Wager, M.D.
JD

Jeffrey D. Wager, M.D.

Chief Executive Officer

Spexis

Spexis Pipeline

DrugIndicationPhase
ColiFin®Cystic FibrosisPhase 3
Inhaled Murepavadin (OMPTA)Gram-negative Bacterial InfectionsPhase 1
OMPTA (LPS/BamA)Gram-negative Bacterial InfectionsPre-clinical
OMPTA (LptA Thanatin)Gram-negative Bacterial InfectionsPre-clinical
Macrocycle Oncology LeadsOncologyPre-clinical